...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Comparative Evaluation of the in-vitro Activity of Six ?-lactam/?-lactamase Inhibitor Combinations against Gram Negative Bacilli
【24h】

Comparative Evaluation of the in-vitro Activity of Six ?-lactam/?-lactamase Inhibitor Combinations against Gram Negative Bacilli

机译：六种β-内酰胺/β-内酰胺酶抑制剂组合对革兰氏阴性杆菌体外活性的比较评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The extensive use of the ? -lactam antibiotics in hospitals and in the community has created major resistance problems which has led to increased morbidity, mortality and healthcare costs. The use of the ? -lactamase inhibitors in combination with the ? -lactam antibiotics is currently the most successful strategy used for circumventing the resistance mechanisms.Objective: To evaluate the in-vitro activity of six commercially available ? -lactam/ ? -lactamase inhibitor combinations against Gram Negative Bacilli (GNB).Materials and Methods: A total of 384 non duplicate, consecutive, gram negative bacilli (278 Enterobacteriaceae and 106 non fermenters) isolated from various clinical samples were subjected to antimicrobial sensitivity testing by the Kirby-Bauer method. The following ? -lactam/ ? -lactamase inhibitor combinations were tested: amoxycillin-clavulanic acid, ampicillin-sulbactam, cefoperazone-sulbactam, piperacillin-tazobactam, cefepime-tazobactam and ticarcillin-clavulanic acid.Results: Against the Enterobacteriacae, the sensitivity of Cefepime- tazobactam was 90. 64%, followed by Cefoperazone-sulbactam (84.89%) and Piperacillin - tazobactam (53.95 %). The sensitivity of the non fermenters was the highest for Cefepime- tazobactam (49.04%) and was least for Ampicillin-sulbactam and Amoxycillin-clavulanic acid (4.71% each). Cefepime-tazobactam was sensitive for all the extended spectrum B-lactamase (ESBL) isolates.Conclusion: Among the six ? -lactam/ ? -lactamase inhibitor combinations tested, Cefepime-tazobactam exhibited the best in-vitro activity against the gram negative bacilli isolated at our centre.
机译：背景：？的广泛使用？ -β-内酰胺类抗生素在医院和社区中已引起严重的耐药性问题，导致发病率，死亡率和医疗保健费用增加。使用？ -内酰胺酶抑制剂与？ β-内酰胺类抗生素是目前最成功的规避耐药机制的策略。目的：评估六种市售可得的体外活性。 -内酰胺/ -内酰胺酶抑制剂组合对抗革兰氏阴性杆菌（GNB）。材料与方法：对从各种临床样品中分离出的共384种非重复，连续，革兰氏阴性细菌（278种肠杆菌科细菌和106种非发酵菌）进行了Kirby抗菌敏感性测试-鲍尔方法。以下 ？ -内酰胺/测试了β-内酰胺酶抑制剂的组合：阿莫西林-克拉维酸，氨苄青霉素-舒巴坦，头孢哌酮-舒巴坦，哌拉西林-他唑巴坦，头孢吡肟-他唑巴坦和替卡西林-克拉维酸。结果：针对肠杆菌，头孢吡肟90-他唑巴坦的敏感性为90％。 ，其次是头孢哌酮舒巴坦（84.89％）和哌拉西林-他唑巴坦（53.95％）。非发酵罐对头孢吡肟-他唑巴坦的敏感性最高（49.04％），对氨苄青霉素-舒巴坦和阿莫西林-克拉维酸的敏感性最低（各4.71％）。头孢吡肟他唑巴坦对所有扩展谱的B-内酰胺酶（ESBL）分离株均敏感。 -内酰胺/ -内酰胺酶抑制剂组合经过测试，头孢吡肟-他唑巴坦对我们中心分离出的革兰氏阴性杆菌表现出最好的体外活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号